To counterbalance the deleterious effect of constitutive type I IFN activation, a minor subset of SLE patients (5%) present neutralizing type I anti-IFN Abs and this subset is associated with lower disease activity [52,53]. Here, DDX41 is linked to systemic lupus erythematosus.